What 2020 means for the life sciences
BIO 2020: AI patents and secrets
Andrii Vodolazhskyi / Shutterstock.com
As AI becomes a crucial weapon in the battle against the global pandemic, companies in the field need to ensure that their valuable IP is protected, as Mao Xiao Hong and Danny Yap of IPOS International explain.
Nine days before the World Health Organization officially notified the public of a flu-like outbreak in China, BlueDot, a Canadian artificial intelligence (AI) startup, warned its clients of a potential outbreak near a market in Wuhan, China.
On December 31, 2019, BlueDot, using machine learning and natural-language processing to scour through foreign language news reports and medical bulletins in many languages, alerted public health officials in Canada and elsewhere of the outbreak and identified the countries that were most at risk, based on airline ticket data.
Breaking new ground
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
IPOS International, COVID-19, WHO, artificial intelligence, machine learning, Alibaba, pandemic, patents, innovation, healthcare, software, trade secrets